Univariate and multivariable generalised estimating equations for wrist scores
| Status | Change | |||||||
| Univariate | Multivariable | Univariate | Multivariable | |||||
| β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | |
| HAQ† | ||||||||
| MRI synovitis | 0.06 (0.04 to 0.07) | <0.001 | 0.00 (−0.02 to 0.02) | 0.97 | 0.08 (0.04 to 0.12) | <0.001 | −0.01 (−0.04 to 0.03) | 0.72 |
| MRI tenosynovitis | 0.04 (0.03 to 0.05) | <0.001 | 0.01 (0.00 to 0.02) | 0.14 | 0.07 (0.04 to 0.09) | <0.001 | 0.02 (0.00 to 0.04) | 0.05 |
| MRI osteitis | 0.01 (0.01 to 0.02) | <0.001 | 0.04 (0.00 to 0.01) | 0.03 | 0.02 (0.01 to 0.04) | 0.001 | 0.01 (0.00 to 0.02) | 0.04 |
| MRI erosion | −0.03 (−0.11 to 0.05) | 0.51 | 0.08 (−0.09 to 0.26) | 0.35 | ||||
| MRI JSN | −0.02 (−0.09 to 0.06) | 0.67 | −0.02 (−0.25 to 0.21) | 0.84 | ||||
| MRI combined inflammation* | 0.02 (0.01 to 0.02) | <0.001 | 0.00 (0.00 to 0.01) | 0.16 | 0.03 (0.01 to 0.04) | <0.001 | 0.01 (0.00 to 0.02) | 0.01 |
| MRI combined damage* | −0.06 (−0.12 to 0.02) | 0.16 | 0.07 (−0.11 to 0.24) | 0.44 | ||||
| VAS-PtGlobal† | ||||||||
| MRI synovitis | 0.10 (0.08 to 0.13) | <0.001 | 0.01 (−0.02 to 0.04) | 0.48 | 4.13 (2.55 to 5.71) | <0.001 | 1.79 (0.34 to 3.23) | 0.02 |
| MRI tenosynovitis | 0.06 (0.05 to 0.07) | <0.001 | 0.01 (−0.01 to 0.02) | 0.29 | 2.12 (1.14 to 3.09) | <0.001 | −0.08 (−1.08 to 0.92) | 0.88 |
| MRI osteitis | 0.01 (0.00 to 0.02) | 0.004 | 0.00 (−0.01 to 0.01) | 0.92 | 0.90 (0.22 to 1.58) | 0.01 | 0.21 (−0.25 to 0.66) | 0.37 |
| MRI erosion | −0.09 (−0.20 to 0.02) | 0.11 | 3.10 (−4.69 to 10.90) | 0.44 | ||||
| MRI JSN | −0.03 (−0.16 to 0.10) | 0.65 | −3.33 (−12.06 to 5.40) | 0.46 | ||||
| MRI combined inflammation* | 0.02 (0.01 to 0.03) | <0.001 | 0.00 (0.00 to 0.01) | 0.10 | 0.96 (0.48 to 1.44) | <0.001 | 0.42 (0.06 to 0.78) | 0.02 |
| MRI combined damage* | −0.09 (−0.20 to 0.02) | 0.12 | 1.62 (−5.92 to 9.16) | 0.67 | ||||
| VAS-pain† | ||||||||
| MRI synovitis | 0.09 (0.05 to 0.13) | <0.001 | 0.02 (−0.01 to 0.05) | 0.14 | 4.64 (3.20 to 6.08) | <0.001 | 2.20 (0.87 to 3.53) | 0.001 |
| MRI tenosynovitis | 0.05 (0.03 to 0.06) | <0.001 | 0.01 (−0.01 to 0.05) | 0.19 | 2.19 (1.30 to 3.09) | <0.001 | −0.02 (−0.91 to 0.87) | 0.96 |
| MRI osteitis | 0.01 (0.00 to 0.02) | 0.20 | 0.89 (0.21 to 1.57) | 0.01 | 0.21 (−0.27 to 0.68) | 0.39 | ||
| MRI erosion | −0.06 (−0.17 to 0.05) | 0.28 | 0.13 (−6.85 to 7.10) | 0.97 | ||||
| MRI JSN | 0.01 (−0.10 to 0.12) | 0.83 | −1.24 (−9.09 to 6.61) | 0.76 | ||||
| MRI combined inflammation* | 0.02 (0.01 to 0.02) | <0.001 | 0.00 (0.00 to 0.01) | 0.16 | 1.02 (0.55 to 1.49) | <0.001 | 0.48 (0.11 to 0.85) | 0.01 |
| MRI combined damage* | −0.08 (−0.19 to 0.03) | 0.15 | −3.74 (−10.12 to 2.65) | 0.25 | ||||
*If sum scores in univariate GEE had a p-value≤0.10, this was included in a separate multivariable GEE model with CRP and SJC.
†Log-transformed for status scores.
Association between MRI parameters and patient-reported outcomes for status scores and change scores. All generalised estimating equations (GEE) were adjusted for age and sex. MRI parameters with a univariate p≤0.10 were included in multivariable GEE analysis where CRP and SJC were incorporated.
HAQ, health assessment questionnaire; JSN, joint space narrowing; PtGlobal, patient global; VAS, visual analogue scale.